What is classed as a Medicine in the UK? (2025 Edition)

What is classed as a medicine in the United Kingdom:

A Practical Regulatory Guide for Pharmaceutical Wholesalers & Distributors

Understanding this is fundamental for any organisation involved in the wholesale distribution, storage, or supply of medicinal products.

The UK maintains one of the most tightly regulated medicines supply chains in the world, overseen primarily by the Medicines and Healthcare products Regulatory Agency (MHRA) and underpinned by national legislation, most notably the Human Medicines Regulations 2012 (HMR 2012).

For wholesalers, distributors, and pharmaceutical outlets, navigating this landscape is not simply a compliance exercise, it is a statutory responsibility that directly impacts patient safety, public health, and the integrity of the wider supply chain.

In this blog we explore how UK law defines a medicine, the types of products captured under this definition, how borderline products are assessed, the obligations placed upon wholesale distributors, and the consequences of noncompliance, including the risks associated with falsified medicines entering the supply chain.

The Legal Definition of a Medicinal Product

Under the Human Medicines Regulations 2012, a medicinal product is defined using a two-limb test:

• • • Presentation limb – Any substance presented as having properties for treating or preventing disease in human beings.
    • Function limb – Any substance that may be used in or administered to human beings with a view to restoring, correcting, or modifying physiological functions by exerting a pharmacological, immunological, or metabolic action, or making a medical diagnosis.

A product only needs to fall under one of these limbs to be classified as a medicinal product.

This definition is intentionally broad to ensure that any product that could affect human physiology in a clinically meaningful way remains within the scope of medicines regulation.

Examples of Products Classified as Medicines

The medicinal category extends beyond traditional tablets, capsules, and injections. Products commonly classified as medicines include:

• • • Analgesics, antibiotics, antivirals, and other therapeutic pharmaceuticals
    • Vaccines, immunoglobulins, and biological medicinal products
    • Medicated creams, gels, ointments, and transdermal patches
    • Hormonal preparations, including contraceptives
    • Diagnostic agents used in clinical settings
    • Anaesthetics, both topical and injectable
    • Products exerting systemic pharmacological action, even if applied locally

In practice, even products that appear cosmetic or supplementary, for example, vitamins, minerals or food supplements, may fall under the scope of medicines regulation if they are prescribed for therapeutic benefits or to exert a physiological effect.

Borderline Products: When Classification Is Not Clear-Cut

Borderline products occupy the grey area between medicines, medical devices, cosmetics, supplements, and general consumer products. These include items such as:

• • • Herbal and traditional remedies
    • Products marketed for “wellbeing” but implying therapeutic benefit
    • Topical products with active ingredients that may produce pharmacological action
    • Vitamins and minerals presented in high doses
    • Products making claims regarding anxiety reduction, improved sleep, weight loss, or enhanced cognitive performance

The MHRA assesses borderline products on a case-by-case basis based on factors such as:

• • • Claims made on the label, marketing material, or website
    • Active ingredients and their known pharmacological effects
    • Dosage, concentration, and route of administration
    • The product’s overall presentation to the public

If the MHRA determines a product meets the definition of a medicinal product, it must not be sold, supplied, stored, or distributed as anything other than a licensed medicine unless exempt under specific categories (such as Traditional Herbal Registration or ‘Specials’).

Further information relating to borderline medicines can be found in MHRA Guidance Note 8.

It should be noted that producing a vitamin supplement that looks like a pharmaceutical product and adding “This is a food supplement” on the front of the packaging, is highly likely to be considered a “stealth medicine.”

UK Regulatory Framework Governing Wholesale Distribution

Any company involved in the wholesale distribution of medicinal products must comply with the obligations under the Human Medicines Regulations 2012, Good Distribution Practice (GDP) requirements, and MHRA guidance.

A wholesaler must hold a Wholesale Distribution Authorisation (WDA(H)) before handling prescription or over-the-counter medicines at wholesale level. Key obligations include:

• • • Ensuring all medicinal products are sourced exclusively from authorised and approved suppliers
    • Supplying medicinal products only to other authorised recipients (e.g., WDA(H) holders, pharmacies, hospitals)
    • Maintaining secure, temperature-controlled storage that complies with GDP
    • Implementing robust quality systems, including SOPs, deviation management, risk management, and training
    • Ensuring products are transported under conditions that protect their quality and integrity
    • Conducting due diligence checks on all supply chain partners and customers
    • Maintaining full traceability through comprehensive documentation and record-keeping
    • Reporting complaints, defects, and recalls promptly to the MHRA
    • Ensuring responsible personnel, including the Responsible Person (RP), oversee GDP compliance

Post-Brexit, the UK continues to maintain alignment with core principles previously associated with the EU Falsified Medicines Directive (FMD), although the UK no longer participates in the EU verification system. Instead, the MHRA requires strengthened due diligence and vigilance from wholesale distributors.

If you are supplying medicinal products into Northern Ireland then you need to be aware of the Windsor Framework.

Ensuring Protection Against Falsified Medicines

Falsified medicines pose a serious risk to patient safety.

They may contain incorrect or harmful ingredients, be improperly manufactured, or misrepresent their identity or origin i.e., stolen genuine product that has been reintroduced to the supply chain by OCGs or bad actors

Wholesalers must be proactive in preventing falsified products entering the supply chain by:

• • • • Procuring medicines only from authorised manufacturers, Marketing Authorisation holders, or licensed wholesalers
      • Conducting enhanced due diligence on suppliers, verifying licences, legitimacy, trading history, and supply chain transparency
      • Checking packaging and tamper-evident features for signs of alteration or counterfeiting
      • Investigating any inconsistencies in batch numbers, expiry dates, or documentation
      • Monitoring unusual order patterns or supply shortages that may indicate illicit sources
      • Maintaining comprehensive records that demonstrate the full traceability of every batch
      • Understanding the supply chain and the source of medicinal products
      • Following the money chain, and not being tricked into paying monies to personal accounts or receiving payment by personal credit cards/bank transfers

Failure to identify falsified medicines can result in severe regulatory action, including suspension of authorisation, product recalls, and possible criminal investigation.

Consequences of Supplying Medicinal Products Without Correct Authorisation

Supplying medicinal products without the appropriate authorisation is a criminal offence under the Human Medicines Regulations 2012.

Consequences include:

• • • Criminal prosecution resulting in fines or imprisonment
    • Revocation or suspension of a Wholesale Distribution Authorisation
    • MHRA enforcement action, including warnings, prohibition notices, and seizure of stock
    • Reputational damage that can irreparably harm a business
    • Civil liability if harm occurs to patients
    • Increased scrutiny and compliance audits in the future

The MHRA has wide enforcement powers, and in recent years has demonstrated a willingness to take decisive action against organisations that knowingly or inadvertently breach medicines legislation.

Why Classification Matters: Impact on Wholesalers and Distributors

Misclassifying a product as a food supplement or general consumer item when it should legally be treated as a medicine exposes businesses to significant regulatory risk. Even minor therapeutic claims can bring a product within the remit of medicines regulation.

For wholesale distributors, accurate classification determines:

• • • Whether the product can legally be stored or handled under a WDA(H)
    • Whether the recipient must also be authorised
    • The level of GDP oversight required
    • Labelling, batch tracking, and quality documentation requirements
    • Whether additional pharmacovigilance or reporting obligations apply

Failing to recognise that a product qualifies as a medicinal product can inadvertently lead to unlicensed supply, a serious breach of UK medicines law.
See MHRA Guidance Note 14 for more information on the sale and supply of unlicensed medicines.

Conclusion: Maintaining Compliance in a Complex Landscape

The definition of a medicinal product in the UK is intentionally broad, ensuring that any product capable of affecting human health through therapeutic claims or physiological effects is subject to stringent regulation. For wholesalers and distributors, understanding these definitions and their practical implications is essential.

To operate safely and legally, organisations must:

• • • Comprehend how the UK classifies medicines, including borderline products
    • Ensure full compliance with the Human Medicines Regulations 2012 and MHRA guidance
    • Maintain rigorous GDP systems that protect the integrity of the supply chain
    • Exercise vigilant due diligence to prevent falsified products entering circulation

By adhering to these principles, wholesalers play a vital role in safeguarding public health and supporting a secure, reliable medicines supply chain.

Paradigm Shift have consultants who can review the scope of your WDA (H) against your product range and work with you to ensure that your licence truly reflects the products you supply to your customers. We pride ourselves on selecting people who are no-nonsense and have done the job, so understand your challenges, rather than say “you can try this” or “The Green Guide says.”

Contact us today for more information.

In addition, GDPTraining.co.uk offers a wide range of GDP online training courses including, falsified medicines, unlicensed medicines and GDP Awareness.  Find out more about our courses here.